Dpb Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.05 Cr
as on 11-09-2024
- Paid Up Capital ₹ 3.13 Cr
as on 11-09-2024
- Company Age 6 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 60.00 Cr
as on 11-09-2024
- Revenue 29.02%
(FY 2023)
- Profit -20.89%
(FY 2023)
- Ebitda -16.85%
(FY 2023)
- Net Worth 40.02%
(FY 2023)
- Total Assets 78.57%
(FY 2023)
About Dpb Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.05 Cr and a paid-up capital of Rs 3.13 Cr.
The company currently has active open charges totaling ₹60.00 Cr.
Devang Ajmera, Piyush Ajmera, and Bhavin Ajmera serve as directors at the Company.
- CIN/LLPIN
U24304MH2018PLC308316
- Company No.
308316
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
20 Apr 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Dpb Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Devang Ajmera  | Director | 20-Apr-2018 | Current |
| Piyush Ajmera | Director | 20-Apr-2018 | Current |
| Bhavin Ajmera | Director | 20-Apr-2018 | Current |
Financial Performance and Corporate Structure Insights of Dpb Pharmaceuticals.
Dpb Pharmaceuticals Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 29.02% increase. The company also saw a substantial fall in profitability, with a 20.89% decrease in profit. The company's net worth Soared by an impressive increase of 40.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dpb Pharmaceuticals?
In 2023, Dpb Pharmaceuticals had a promoter holding of 100.00%. The company had 2 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vardhman Chemtech LimitedActive 28 years 4 monthsDevang Ajmera, Piyush Ajmera and 1 more are mutual person
- Dpb Antibiotics Private LimitedActive 14 years 8 months
Devang Ajmera, Piyush Ajmera and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 26 Mar 2024 | ₹20.00 Cr | Open |
Hdfc Bank Limited Creation Date: 19 Aug 2022 | ₹10.00 Cr | Open |
Others Creation Date: 24 Jun 2022 | ₹20.00 Cr | Open |
How Many Employees Work at Dpb Pharmaceuticals?
Unlock and access historical data on people associated with Dpb Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dpb Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dpb Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
